Go to any of the major interventional cardiology clinical conferences these days like TCT or EuroPCR and the hottest therapeutic area is clearly structural heart disease, particularly catheter-based heart valve therapy. Similarly, the hottest major interventional cardiology company is clearly Abbott Vascular, a division of Abbott Laboratories Inc., by virtue of the success of its Xience V drug-eluting stent. Dealmaking logic would dictate that Abbott, which currently does not have a play in structural heart, should do an acquisition to get into the catheter-based heart valve market. Sometimes logic actually prevails in M&A and this is one of those cases, with Abbott acquiring Evalve Inc., the leader in the catheter-based mitral valve space. [See Deal] (See "Evalve: Leading the Valve Revolution," IN VIVO, September 2006 Also see "Evalve: Leading the Valve Revolution" - In Vivo, 1 September, 2006..)
Chip Hance, president of Abbott Vascular, notes that the company has been looking at opportunities to enter the structural heart...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?